Pathologic complete responses after chemotherapy plus figitumumab in stage IV non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 29, Issue 7, 2011, Pages

  Corral, Jesús ^a   López Villalobos, José L ^a   Gomez Izquierdo, Lourdes ^a   Borrego, Isabel ^a   Paz Ares, Luis ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; ERLOTINIB; FIGITUMUMAB; FLUORODEOXYGLUCOSE F 18; GEMCITABINE; PACLITAXEL;

ADULT; ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG TOLERABILITY; FEMALE; HISTOPATHOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; THORACOTOMY; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY, NEEDLE; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MIDDLE AGED; NEOPLASM STAGING; PNEUMONECTOMY; POSITRON-EMISSION TOMOGRAPHY; REMISSION INDUCTION; SMOKING; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79952293262     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.31.4641     Document Type: Article

References (15)

1. Karp DD, Paz-Ares LG, Novello S, et al: Phase II study of the efficacy of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol 27:2516-2522, 2009
2. Ramalingam S, Belani C: Systemic chemotherapy for advanced non-small cell lung cancer: Recent advances and future directions. Oncologist 13:5-13, 2008
3. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2008. CA Cancer J Clin 58:71-96, 2008
4. National Comprehensive Cancer Network: Non-Small-Cell Lung Cancer NCCN Guidelines for Patients, version 2010. http://www.nccn.org/professionals/ physician-gls/PDF/nscl.pdf
5. Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-98, 2002 (Pubitemid 34438899)
6. Reck M, von Pawel J, Zatloukal P, et al: Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 27:1227-1234, 2009
7. Pirker R, Pereira JR, Szczesna A, et al: Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 373:1525-1531, 2009
8. Hung P-S, Kao S-Y, Shih Y-H, et al: Insulin-like growth factor binding protein-5 (IGFBP-5) suppresses the tumourigenesis of head and neck squamous cell carcinoma. J Pathol 214:368-376, 2008 (Pubitemid 351212392)
9. Pollak M: Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8:915-928, 2008
10. Pollak M: Targeting insulin and insulin-like growth factor signalling in oncology. Curr Opin Pharmacol 8:384-392, 2008
11. Dziadziuszko R, Camidge DR, Hirsch FR: The insulin-like growth factor pathway in lung cancer. J Thorac Oncol 3:815-818, 2008
12. Samani AA, Yakar S, LeRoith D, et al: The role of the IGF system in cancer growth and metastasis: Overview and recent insights. Endocr Rev 28:20-47, 2007 (Pubitemid 46220849)
13. Chang YS, Kong G, Sun S, et al: Clinical significance of insulin-like growth factor-binding protein-3 expression in stage I non-small cell lung cancer. Clin Cancer Res 8:3796-3802, 2002 (Pubitemid 35424772)
14. Yu H, Spitz MR, Mistry J, et al: Plasma levels of insulin-like growth factor-I and lung cancer risk: A case-control analysis. J Natl Cancer Inst 91:151-156, 1999 (Pubitemid 29042692)
15. Cohen BD, Baker DA, Soderstrom C, et al: Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res 11:2063-2073, 2005 (Pubitemid 40471873)